Literature DB >> 29407775

Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice.

Linlin Zhang1, Huizong Su1, Yue Li1, Yujuan Fan1, Qian Wang1, Jian Jiang1, Yiyang Hu1, Gaofeng Chen1, Bo Tan2, Furong Qiu3.   

Abstract

The aim of this study was to determine the effect of ursodeoxycholic acid (UDCA) on the alpha-naphthylisothiocyanate (ANIT)-induced acute and recovery stage of cholestasis model mice. In the acute stage of model mice, pretreatment with UDCA (25, 50, and 100 mg·kg-1, ig) for 12 days prior to ANIT administration (50 mg·kg-1, ig) resulted in the dramatic increase in serum biochemistry, with aggrevation of bile infarcts and hepatocyte necrosis. The elevation of beta-muricholic acid (β-MCA), cholic acid (CA), and taurocholic acid (TCA) in serum and liver, and reduction of these bile acids (BAs) in bile was observed. In contrast, in the recovery stage of model mice, treatment with UDCA (25, 50, and 100 mg·kg-1, ig) for 7 days after ANIT administration (50 mg·kg-1, ig) resulted in the significant decrease in levels of serum alanine aminotransferase (ALT) and total bile acid (TBA). Liver injury was attenuated, and the levels of TBA, CA, TCA, and β-MCA in the liver were significantly decreased. Additionally, UDCA can upregulate expression of BSEP, but it cannot upregulate expression of AE2. UDCA, which induced BSEP to increase bile acid-dependent bile flow, aggravated cholestasis and liver injury when the bile duct was obstructed in the acute stage of injury in model mice. In contrast, UDCA alleviated cholestasis and liver injury induced by ANIT when the obstruction was improved in the recovery stage.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Alpha-naphthylisothiocyanate; Hepatotoxicity; Intrahepatic cholestasis; Ursodeoxycholic acid

Mesh:

Substances:

Year:  2018        PMID: 29407775     DOI: 10.1016/j.taap.2018.01.019

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  4 in total

1.  Integrated Lipidomics and Metabolomics Study of Four Chemically Induced Mouse Models of Acute Intrahepatic Cholestasis.

Authors:  Weiwei Li; Hui Chen; Yihan Qian; Shouchuan Wang; Zichen Luo; Jinjun Shan; Xiaoni Kong; Yueqiu Gao
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

2.  Hepatoprotective Effects of Glycyrrhetinic Acid on Lithocholic Acid-Induced Cholestatic Liver Injury Through Choleretic and Anti-Inflammatory Mechanisms.

Authors:  Qian Wang; Guo-Chao Song; Feng-Yi Weng; Bin Zou; Jing-Yi Jin; Dong-Ming Yan; Bo Tan; Jing Zhao; Yue Li; Fu-Rong Qiu
Journal:  Front Pharmacol       Date:  2022-05-31       Impact factor: 5.988

3.  Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ12,14 -PGJ2 and Nogo.

Authors:  Shuang Zhang; Miao Yu; Fangling Guo; Xiaoxiao Yang; Yuanli Chen; Chuanrui Ma; Qi Li; Zhuo Wei; Xiaoju Li; Hua Wang; Huaqing Hu; Yujue Zhang; Derun Kong; Qing Robert Miao; Wenquan Hu; David P Hajjar; Yan Zhu; Jihong Han; Yajun Duan
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

4.  Effect of Different Ratios of Yinchen and Gancao Decoction on ANIT-Treated Cholestatic Liver Injury in Mice and Its Potential Underlying Mechanism.

Authors:  Huizong Su; Qian Wang; Yue Li; Jingyi Jin; Bo Tan; Dongming Yan; Bin Zou; Guochao Song; Fengyi Weng; Furong Qiu
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.